China Isotope & Radiation Corporation (1763) investor relations material

Executive summary

• Revenue for 2025 was RMB7,187.7 million, down 5.1% year-over-year, mainly due to delays in centralized procurement of large-scale medical equipment.

• Net profit was RMB664.5 million, a 24.4% decrease year-over-year; net profit attributable to the parent was RMB327.4 million, down 19.5%.

• Excluding additional tax and late payment penalties, adjusted net profit attributable to the parent rose 12.5% year-over-year.

• The Board recommended a final cash dividend of RMB0.2264 per share.

Financial highlights

• Gross profit was RMB3,621.6 million, down 1.7% year-over-year; gross margin improved to 50.4% from 48.6%.

• Other income increased 45% to RMB112.4 million, mainly from higher dividend income and lower losses on disposals.

• Selling and distribution expenses fell 10.7% to RMB1,449.2 million; administrative and R&D costs rose 16.7% to RMB1,226.2 million due to tax penalties.

• Finance costs increased 46.7% to RMB71.0 million due to higher external borrowing.

• Effective tax rate rose to 33.8% from 15.9% due to supplementary tax payments.

• Basic and diluted EPS was RMB1.02, down from RMB1.27 in 2024.

Outlook and guidance

• Focus areas for 2026 include strengthening innovation, market development, international expansion, production capacity, capital operations, reform, and governance.

• Plans to accelerate clinical trials, expand exports, and enhance digital transformation and quality management.